These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 15907150)

  • 1. Social anxiety disorder : current treatment recommendations.
    Muller JE; Koen L; Seedat S; Stein DJ
    CNS Drugs; 2005; 19(5):377-91. PubMed ID: 15907150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evidence-based pharmacological treatment of social anxiety disorder.
    Blanco C; Raza MS; Schneier FR; Liebowitz MR
    Int J Neuropsychopharmacol; 2003 Dec; 6(4):427-42. PubMed ID: 14609440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy of social anxiety disorder: what does the evidence tell us?
    Davidson JR
    J Clin Psychiatry; 2006; 67 Suppl 12():20-6. PubMed ID: 17092192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregabalin for the treatment of social anxiety disorder.
    Kawalec P; Cierniak A; Pilc A; Nowak G
    Expert Opin Investig Drugs; 2015 Apr; 24(4):585-94. PubMed ID: 25361817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evidence-based pharmacotherapy of social anxiety disorder.
    Blanco C; Bragdon LB; Schneier FR; Liebowitz MR
    Int J Neuropsychopharmacol; 2013 Feb; 16(1):235-49. PubMed ID: 22436306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder.
    Stein DJ; Cameron A; Amrein R; Montgomery SA;
    Int Clin Psychopharmacol; 2002 Jul; 17(4):161-70. PubMed ID: 12131599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining an appropriate management strategy for social anxiety disorder.
    Davidson JR
    Int Clin Psychopharmacol; 2000 Jul; 15 Suppl 1():S13-7. PubMed ID: 10994678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the epidemiology and approaches to the treatment of social anxiety disorder.
    Sareen L; Stein M
    Drugs; 2000 Mar; 59(3):497-509. PubMed ID: 10776832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in understanding and treating social anxiety disorder.
    Westenberg HG
    CNS Spectr; 2009 Feb; 14(2 Suppl 3):24-33. PubMed ID: 19238127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The lifelong course of social anxiety disorder: a clinical perspective.
    Keller MB
    Acta Psychiatr Scand Suppl; 2003; (417):85-94. PubMed ID: 12950439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial.
    Stein DJ; Westenberg HG; Yang H; Li D; Barbato LM
    Int J Neuropsychopharmacol; 2003 Dec; 6(4):317-23. PubMed ID: 14604447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy of social anxiety disorder at the turn of the millennium.
    Van Ameringen M; Mancini C
    Psychiatr Clin North Am; 2001 Dec; 24(4):783-803. PubMed ID: 11723633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamine oxidase inhibitors and alprazolam in the treatment of panic disorder and agoraphobia.
    Sheehan DV
    Psychiatr Clin North Am; 1985 Mar; 8(1):49-62. PubMed ID: 2859580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological treatment of social anxiety disorder.
    Masdrakis VG; Turic D; Baldwin DS
    Mod Trends Pharmacopsychiatry; 2013; 29():144-53. PubMed ID: 25225024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating neurobiology and psychopathology into evidence-based treatment of social anxiety disorder.
    Liebowitz MR; Ninan PT; Schneier FR; Blanco C
    CNS Spectr; 2005 Oct; 10(10):suppl13 1-11; discussion 12-3; quiz 14-5. PubMed ID: 16404800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Issues and controversies surrounding the diagnosis and treatment of social anxiety disorder.
    Dalrymple KL
    Expert Rev Neurother; 2012 Aug; 12(8):993-1008; quiz 1009. PubMed ID: 23002942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Social anxiety disorder.
    Kaminer D; Stein DJ
    World J Biol Psychiatry; 2003 Jul; 4(3):103-10. PubMed ID: 12872202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder.
    Pollack MH; Van Ameringen M; Simon NM; Worthington JW; Hoge EA; Keshaviah A; Stein MB
    Am J Psychiatry; 2014 Jan; 171(1):44-53. PubMed ID: 24399428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluvoxamine: a review of its therapeutic potential in the management of anxiety disorders in children and adolescents.
    Cheer SM; Figgitt DP
    Paediatr Drugs; 2001; 3(10):763-81. PubMed ID: 11706925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comorbid social withdrawal (hikikomori) in outpatients with social anxiety disorder: clinical characteristics and treatment response in a case series.
    Nagata T; Yamada H; Teo AR; Yoshimura C; Nakajima T; van Vliet I
    Int J Soc Psychiatry; 2013 Feb; 59(1):73-8. PubMed ID: 21997765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.